A randomized controlled trial evaluating the erythropoiesis stimulating agent sparing potential of a vitamin E-bonded polysulfone dialysis membrane

Nephrology Dialysis Transplantation

Volumn 29, Issue 3, 2014, Pages 649-656

  Lines, Simon W ^a,b   Carter, Angela M ^b   Dunn, Emma J ^a   Lindley, Elizabeth J ^a   Tattersall, James E ^a   Wright, Mark J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anaemia; Haemodialysis; Inflammation; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; C REACTIVE PROTEIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; POLYSULFONE; ANTIANEMIC AGENT; ARTIFICIAL MEMBRANE; ERYTHROPOIETIN; POLYMER; POLYSULFONE P 1700; SULFONE;

ADULT; ANEMIA; ARTICLE; BLOOD EXAMINATION; CHEMICAL BOND; COMPUTER ANALYSIS; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DIALYSIS MEMBRANE; ERYTHROPOIESIS; ESA RESISTANCE INDEX; FEMALE; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION RESEARCH; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; AGED; ANALOGS AND DERIVATIVES; ARTIFICIAL MEMBRANE; CHEMISTRY; DRUG RESISTANCE; KIDNEY FAILURE, CHRONIC; METABOLISM; RENAL REPLACEMENT THERAPY;

AGED; C-REACTIVE PROTEIN; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; POLYMERS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SULFONES; VITAMIN E;

EID: 84895724989     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft481     Document Type: Article

References (31)

1. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989; 35: 134-148
2. Macdougall IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens 1994; 3: 620-625
3. Wiswedel I, Peter D, Gardemann A et al. Serum concentrations of F2-isoprostanes and 4-hydroxynonenal in hemodialysis patients in relation to inflammation and renal anemia. Biomark Insights 2008; 3: 419-428
4. Siems W, Carluccio F, Grune T et al. Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia. Clin Nephrol 2002; 58(Suppl 1): S20-S25
5. Gunnell J, Yeun JY, Depner TA et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72
6. Brigelius-Flohe R. Vitamin E: the shrew waiting to be tamed. Free Radic Biol Med 2009; 46: 543-554
7. Cruz DN, De Cal M, Garzotto F et al. Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study. Int J Artif Organs 2008; 31: 545-552
8. Huraib S, Tanimu D, Shaheen F et al. Effect of vitamin-E-modified dialysers on dialyser clotting, erythropoietin and heparin dosage: a comparative crossover study. Am J Nephrol 2000; 20: 364-368
9. Kobayashi S, Moriya H, Aso K et al. Vitamin E-bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells. Kidney Int 2003; 63: 1881-1887
10. Nakatan T, Takemoto Y, Tsuchida AK. The effect of vitamin E-bonded dialyzer membrane on red blood cell survival in hemodialyzed patients. Artif Organs 2003; 27: 214-217
11. Usberti M, Bufano G, Lima G et al. Increased red blood cell survival reduces the need of erythropoietin in hemodialyzed patients treated with exogenous glutathione and vitamin E-modified membrane. Contrib Nephrol 1999; 127: 208-214
12. Usberti M, Gerardi G, Bufano G et al. Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am J Kidney Dis 2002; 40: 590-599
13. Takouli L, Hadjiyannakos D, Metaxaki P et al. Vitamin E-coated cellulose acetate dialysis membrane: long-term effect on inflammation and oxidative stress. Ren Fail 2010; 32: 287-293
14. Kirmizis D, Papagianni A, Belechri AM et al. Effects of vitamin E-coated membrane dialyser on markers of oxidative stress and inflammation in patients on chronic haemodialysis. Nephrol Dial Transplant 2011; 26: 2296-2301
15. Girndt M, Lengler S, Kaul H et al. Prospective crossover trial of the influence of vitamin E-coated dialyzer membranes on T-cell activation and cytokine induction. Am J Kidney Dis 2000; 35: 95-104
16. Mandolfo S, Corradi B, Bucci R et al. Evaluation of the impact of a new synthetic vitamin E-bonded membrane on anemia and rHuEPO requirement in ESRD patients with central venous catheters: a pilot study. Int Urol Nephrol 2012; 44: 1493-1500
17. Calo LA, Naso A, D'Angelo A et al. Molecular biology-based assessment of vitamin E-coated dialyzer effects on oxidative stress, inflammation, and vascular remodeling. Artif Organs 2011; 35: E33-E39
18. Panichi V, Rosati A, Paoletti S et al. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin- stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial. Blood Purif 2011; 32: 7-14
19. Andrulli S, Di Filippo S, Manzoni C et al. Effect of synthetic vitamin Ebonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study. Nephron Clin Pract 2010; 115: c82-c89
20. Morimoto H, Nakao K, Fukuoka K et al. Long-term use of vitamin Ecoated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant 2005; 20: 2775-2782
21. Sanaka T, Mochizuki T, Kinugasa E et al. Randomized controlled openlabel trial of vitamin E-bonded polysulfone dialyzer and erythropoiesisstimulating agent response. Clin J Am Soc Nephrol 2013; 8: 969-978
22. Lines SW, Lindley EJ, Tattersall JE et al. A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: better results for less work. Nephrol Dial Transplant 2012; 27: 2425-2429
23. National Institute for Health and Clinical Excellence, UK. Anaemia Management in Chronic Kidney Disease (Clinical Guideline 39). London: National Institute for Health and Clinical Excellence, 2006
24. The Renal Association. UK Renal Registry: The Thirteenth Annual Report. 2010
25. The Renal Association. UK Renal Registry: The Fourteenth Annual Report. 2011
26. Opatrny K, Jr, Reischig T, Vienken J et al. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of lowand high-flux biocompatible dialysis. Artif Organs 2002; 26: 181-188
27. Locatelli F, Andrulli S, Pecchini F et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1399-1409
28. Richardson D, Lindley EJ, Bartlett C et al. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response. Am J Kidney Dis 2003; 42: 551-560
29. Schneider A, Drechsler C, Krane V et al. The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: results of the MINOXIS study. Clin J Am Soc Nephrol 2012; 7: 52-59
30. Wanner C, Bahner U, Mattern R et al. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 2570-2575
31. Lonnemann G, Novick D, Rubinstein M et al. A switch to high-flux helixone membranes reverses suppressed interferon-gamma production in patients on low-flux dialysis. Blood Purif 2003; 21: 225-231